AU2015252908B2 - Membrane-adherent self-assembled systems for treatment of ocular disorders - Google Patents

Membrane-adherent self-assembled systems for treatment of ocular disorders Download PDF

Info

Publication number
AU2015252908B2
AU2015252908B2 AU2015252908A AU2015252908A AU2015252908B2 AU 2015252908 B2 AU2015252908 B2 AU 2015252908B2 AU 2015252908 A AU2015252908 A AU 2015252908A AU 2015252908 A AU2015252908 A AU 2015252908A AU 2015252908 B2 AU2015252908 B2 AU 2015252908B2
Authority
AU
Australia
Prior art keywords
phase
api
solution
delivery system
liquid crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015252908A
Other languages
English (en)
Other versions
AU2015252908A1 (en
Inventor
Koushik BARMAN
Shikha P. Barman
Anne-Marie Cromwick
Ritesh V. Thekkedath
Kevin Ward
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Integral Biosystems LLC
Original Assignee
Integral Biosystems LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Integral Biosystems LLC filed Critical Integral Biosystems LLC
Publication of AU2015252908A1 publication Critical patent/AU2015252908A1/en
Application granted granted Critical
Publication of AU2015252908B2 publication Critical patent/AU2015252908B2/en
Priority to AU2018201596A priority Critical patent/AU2018201596B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
AU2015252908A 2014-05-01 2015-05-01 Membrane-adherent self-assembled systems for treatment of ocular disorders Active AU2015252908B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2018201596A AU2018201596B2 (en) 2014-05-01 2018-03-06 Membrane-adherent self-assembled systems for treatment of ocular disorders

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461987012P 2014-05-01 2014-05-01
US61/987,012 2014-05-01
PCT/US2015/028748 WO2015168523A1 (en) 2014-05-01 2015-05-01 Membrane-adherent self-assembled systems for treatment of ocular disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018201596A Division AU2018201596B2 (en) 2014-05-01 2018-03-06 Membrane-adherent self-assembled systems for treatment of ocular disorders

Publications (2)

Publication Number Publication Date
AU2015252908A1 AU2015252908A1 (en) 2016-10-27
AU2015252908B2 true AU2015252908B2 (en) 2017-12-07

Family

ID=54359368

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2015252908A Active AU2015252908B2 (en) 2014-05-01 2015-05-01 Membrane-adherent self-assembled systems for treatment of ocular disorders
AU2018201596A Active AU2018201596B2 (en) 2014-05-01 2018-03-06 Membrane-adherent self-assembled systems for treatment of ocular disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2018201596A Active AU2018201596B2 (en) 2014-05-01 2018-03-06 Membrane-adherent self-assembled systems for treatment of ocular disorders

Country Status (12)

Country Link
US (2) US9901544B2 (https=)
EP (1) EP3137481B1 (https=)
JP (1) JP6452725B2 (https=)
KR (1) KR101890503B1 (https=)
CN (1) CN106459137B (https=)
AU (2) AU2015252908B2 (https=)
CA (1) CA2946373C (https=)
ES (1) ES2924768T3 (https=)
MY (1) MY193694A (https=)
NZ (1) NZ725028A (https=)
SG (1) SG11201608729RA (https=)
WO (1) WO2015168523A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3266446B1 (en) * 2016-07-07 2018-11-21 Laboratorios SALVAT, S.A. Ophthalmic composition comprising castor oil and medium chain triglyceride
US20200121652A1 (en) * 2017-06-16 2020-04-23 The Doshisha Compounds having caspase inhibitory activity, pharmaceutical agent containing said compounds and for treating or preventing corneal endothelial symptoms, disorders, or diseases, and application of said pharmaceutical agent
EP3639854B1 (en) 2017-06-16 2026-01-07 The Doshisha Mtor-inhibitor-containing medicine for treating or preventing fuchs' endothelial corneal dystrophy
KR102115285B1 (ko) * 2017-06-22 2020-05-26 연성정밀화학(주) 녹내장 치료용 점안 조성물
US11129862B2 (en) * 2017-08-30 2021-09-28 Johnson & Johnson Consumer Inc. Ophthalmic compositions
CN111225687A (zh) * 2017-09-01 2020-06-02 默里和普尔企业有限公司 用于治疗眼科疾患的方法和组合物
JP7056480B2 (ja) * 2017-09-08 2022-04-19 ライオン株式会社 眼科用組成物及び涙液油層安定化剤
CN109316440B (zh) * 2018-09-29 2020-12-29 华中科技大学 一种温敏性液晶纳米水凝胶及其制备方法与应用
CN113271979A (zh) 2018-10-24 2021-08-17 费灵有限公司 皮质类固醇的粘膜粘附性药物组合物
GB201818043D0 (en) * 2018-11-05 2018-12-19 Waterford Institute Of Tech Artifical Tears
MX2022014459A (es) * 2020-05-18 2023-02-27 Max Biology Co Ltd Composiciones de lipidos y polimeros y metodos de uso.
US12102632B2 (en) 2020-08-26 2024-10-01 Somerset Therapeutics, Llc Quinolone dispersions
US12016855B2 (en) 2020-08-26 2024-06-25 Somerset Therapeutics, Llc Prednisolone and moxifloxacin compositions and methods
WO2022077060A1 (en) * 2020-10-13 2022-04-21 University Of South Australia Antimicrobial compositions and methods of use

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130303502A1 (en) * 2012-05-08 2013-11-14 Aciex Therapeutics, Inc. Preparations of Hydrophobic Therapeutic Agents, Methods of Manufacture and Use Thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716830B2 (en) * 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
JP4049216B2 (ja) * 2003-05-09 2008-02-20 ポーラ化成工業株式会社 液晶構造を有する製剤
US20070020299A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20050235740A1 (en) * 2004-04-27 2005-10-27 Guido Desie Method to improve the quality of dispersion formulations
CA2578709C (en) * 2004-06-17 2010-06-15 Virun, Inc. Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents
WO2006062875A1 (en) * 2004-12-08 2006-06-15 Merck & Co., Inc. Ophthalmic nanoparticulate formulation of a cyclooxygenase-2 selective inhibitor
CN101137369A (zh) * 2005-02-09 2008-03-05 马库赛特公司 用于眼治疗的制剂
US8906392B2 (en) * 2005-12-16 2014-12-09 University Of Kansas Nanocluster compositions and methods
KR20090053892A (ko) * 2006-07-25 2009-05-28 오스모티카 코프. 점안액
JP2010064995A (ja) * 2008-09-12 2010-03-25 Nikko Chemical Co Ltd 外用消炎鎮痛剤組成物
JP5207420B2 (ja) * 2009-12-25 2013-06-12 株式会社ケムジェネシス 低粘度液晶化合物
CN101773670A (zh) * 2009-12-29 2010-07-14 中山大学 一种液晶药物载体
JP2012017318A (ja) * 2010-06-07 2012-01-26 Nikko Chemical Co Ltd 液晶及びそれを含有する皮膚外用剤
US8772273B2 (en) * 2011-10-04 2014-07-08 Quretino Therapeutics, Inc. Formulations and uses of retinoic acid receptor selective agonists
NZ742005A (en) * 2012-05-03 2019-04-26 Kala Pharmaceuticals Inc Pharmaceutical nanoparticles showing improved mucosal transport
AU2013259872B2 (en) * 2012-05-08 2018-06-28 Nicox Ophthalmics, Inc. Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130303502A1 (en) * 2012-05-08 2013-11-14 Aciex Therapeutics, Inc. Preparations of Hydrophobic Therapeutic Agents, Methods of Manufacture and Use Thereof

Also Published As

Publication number Publication date
WO2015168523A1 (en) 2015-11-05
CN106459137A (zh) 2017-02-22
KR20160147784A (ko) 2016-12-23
CN106459137B (zh) 2019-04-12
EP3137481A4 (en) 2017-12-27
EP3137481B1 (en) 2022-07-06
US20180185275A1 (en) 2018-07-05
US9901544B2 (en) 2018-02-27
AU2018201596A1 (en) 2018-03-29
NZ725028A (en) 2019-01-25
SG11201608729RA (en) 2016-11-29
JP2017514843A (ja) 2017-06-08
US20170049697A1 (en) 2017-02-23
JP6452725B2 (ja) 2019-01-16
US10603273B2 (en) 2020-03-31
KR101890503B1 (ko) 2018-08-21
AU2018201596B2 (en) 2020-02-06
CA2946373A1 (en) 2015-11-05
CA2946373C (en) 2018-07-31
EP3137481A1 (en) 2017-03-08
MY193694A (en) 2022-10-25
AU2015252908A1 (en) 2016-10-27
ES2924768T3 (es) 2022-10-10

Similar Documents

Publication Publication Date Title
AU2018201596B2 (en) Membrane-adherent self-assembled systems for treatment of ocular disorders
Ammar et al. Nanoemulsion as a potential ophthalmic delivery system for dorzolamide hydrochloride
Li et al. A potential new therapeutic system for glaucoma: solid lipid nanoparticles containing methazolamide
TW201703770A (zh) 酪胺酸激酶抑制劑之眼用調配物、其使用方法、及其製備方法
Wang et al. Self-assembled thermoresponsive nanogels prepared by reverse micelle→ positive micelle method for ophthalmic delivery of muscone, a poorly water-soluble drug
CN102802624A (zh) 药物的纳米分散体以及它的制备方法
CN111867562A (zh) 不溶性药物的水性制剂
JP7026609B2 (ja) 微細粒子含有組成物およびその製法
WO2016007114A1 (en) Method of obtaining a pharmacologically active liposomal quercetin-containing product
Jacob et al. Lipid nanoparticles as a promising drug delivery carrier for topical ocular therapy—an overview on recent advances. Pharmaceutics 2022; 14 (3): 533
Wolska et al. Technology of stable, prolonged-release eye-drops containing Cyclosporine A, distributed between lipid matrix and surface of the solid lipid microspheres (SLM)
Jaber et al. Preparation and evaluation of ascorbyl glucoside and ascorbic acid solid in oil nanodispersions for corneal epithelial wound healing
JP2022062172A (ja) 無菌眼用水性プロピオン酸フルチカゾンａ型ナノ結晶懸濁液の調製方法
TWI707684B (zh) 點眼用懸濁製劑
Tuncay Tanriverdi et al. Formulation, characterization, and in vitro release of topical nanoemulsion containing prednisolone-derived corticosteroid
WO2022264184A1 (en) Ophthalmic nano-dispersion composition, a method of preparation thereof, and formulation for corneal epithelial wound healing
HK1234413B (zh) 用於治療眼部病症的膜附著性自組裝體系
HK1234413A1 (en) Membrane-adherent self-assembled systems for treatment of ocular disorders
CN120227380A (zh) 含有黄体酮的药物组合物及应用
BR112017025757B1 (pt) Formulações oftálmicas de inibidores da tirosina quinase e suas composições farmacêuticas

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ BARMAN, SHIKHA P.; THEKKEDATH, RITESH V.; WARD, KEVIN; CROMWICK, ANNE-MARIE AND BARMAN, KOUSHIK

FGA Letters patent sealed or granted (standard patent)